| Exclusion Criteria: | 1) Patient has received any other investigational agents within 30 days of first day of study drug dosing.
2) Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
3) Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
4) Female patients who are pregnant or breast-feeding.
5) Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
6) Patient has a known untreated or unstable brain metastasis.
7) Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
8) Patient has a known diagnosis of human immunodeficiency virus (HIV) infection. HIV patients are at much greater risk of infection when receiving highly myelosuppressive agents (docetaxel and imatinib) and for safety reasons are not eligible for this trial.
9) Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry, unless the disease is rapidly progressing.
10) Patient previously received radiotherapy to >/= 25 % of the bone marrow
11) Patient had a major surgery within 2 weeks prior to study entry.
12) Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
13) Patients must agree not to use herbal remedies or other over-the-counter biologics (i.e. shark cartilage)
14) History of hypersensitivity to docetaxel or other taxane therapy.
15) History of severe hypersensitivity reaction to drugs formulated with polysorbate 80.
16) Prior exposure to imatinib mesylate.
17) Prior exposure to docetaxel systemic therapy for this NSCLC malignancy.
18) Patient treated with more than 1 prior systemic chemotherapy (not including biologic agents e.g. gefitinib, lonafarnib)
19) Participation in an investigational trial within the past 30 days.
20) Patients taking therapeutic levels of warfarin. However, patients receiving 1 mg daily for catheter related anticoagulation are eligible for the study.
21) Prior pericardial effusion requiring intervention such as pericardiocentesis or pericardial window. |